Business
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies
Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the
About this update from Celularity Inc.
[{"type":"text","content":"Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental-derived biomaterials at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering\nFLORHAM PARK, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” “the Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present data on its proprietary extracellular matrices (ECM) at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE), to be held on 24-26 July in Osaka, Japan. The data will include benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products: Biovance®, a decellularized, dehydrated human amniotic membrane (DDHAM)Biovance® 3L, a tri-layer DDHAM (DDHAM-3L)Interfyl®, a human connective tissue matrix (CTM). The data will be presented in an oral session entitled, “Therapeutic Potential of Human Placental-Derived Biomaterials,” by Anna Gosiewska, Ph.D., Vice President, Degenerative Disease Research & Development, on Wednesday, July 26 at 9:00 a.m. JST/ 8:00 p.m. EDT. Benchtop data to be presented demonstrate that: DDHAM modulates macrophage behavior, promoting polarization into M2 phenotype, and serves as a scaffold for endogenous cell attachment and proliferation in wound healing.DDHAM-3L supports human corneal epithelial cell activity and attenuates an inflammatory response over time.CTM supports tenocyte viability, proliferation, and migration, while also maintaining phenotype and attenuating the inflammatory response. CTM also serves as a scaffold for the attachment and proliferation of several cell types, including fibroblasts, monocytes, and endothelial cells, and permits monocyte differentiation into macrophages and vascular tube formation by endothelial cells. In clinical case studies, DDHAM has been used in tendon repair and wound healing, DDHAM-3L has been used in the treatment of anterior basement membrane dystrophy, and CTM has been used to treat wounds and to support the repair of soft tissues. Although these clinical case studies support the potential therapeutic opportunities for these three human placental-derived biomaterial products, additional clinical tria...